Aaron D. Showalter
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Receptor Mechanisms and Signaling, Pancreatic function and diabetes, Neuropeptides and Animal Physiology, Growth Hormone and Insulin-like Growth Factors
Most-Cited Works
- → Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist(2020)445 cited
- → Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors(2004)214 cited
- → Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist(2020)176 cited
- → Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides(2006)146 cited
- → Novel Small Molecule Glucagon-Like Peptide-1 Receptor Agonist Stimulates Insulin Secretion in Rodents and From Human Islets(2010)139 cited
- → Structural determinants of dual incretin receptor agonism by tirzepatide(2022)107 cited
- → Structural insights into probe-dependent positive allosterism of the GLP-1 receptor(2020)93 cited
- → Allosteric Modulation of Endogenous Metabolites as an Avenue for Drug Discovery(2012)78 cited
- → Progesterone Receptor Membrane Component 1 Is a Functional Part of the Glucagon-like Peptide-1 (GLP-1) Receptor Complex in Pancreatic β Cells(2014)65 cited
- → Positive Allosteric Modulation of the Glucagon-like Peptide-1 Receptor by Diverse Electrophiles(2016)60 cited